The cost varies depending on the type of medication and the personalized plan created for you
To view a copy of this license, visit About this article Cite this article Valdecantos, M., Ruiz, L., Pardo, V
The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events
Ozempic (semaglutide) and Mounjaro (tirzepatide) are now strictly covered only when prescribed for Type II diabetes management (their FDA-approved indication)
[DOI] [PMC free article] [PubMed] [Google Scholar] Duval S
Treat these as class-level context from separate trials, not head-to-head results, and remember that average trial weight loss does not predict any individual's response